My Longevity Edge

Rusfertide: The First Weekly Shot That Could Replace Blood Draws for a Rare Blood Cancer

Rusfertide: The First Weekly Shot That Could Replace Blood Draws for a Rare Blood Cancer

⚠️ Medical Disclaimer: This article is for education only. It is not medical advice. Rusfertide is not yet approved by the U.S. FDA. Always talk to your doctor before changing any treatment.

What Is Rusfertide?

Rusfertide is a brand new medicine for a rare blood cancer called polycythemia vera (PV for short). People with PV make too many red blood cells. Their blood gets thick and syrupy. Thick blood can form dangerous clots that cause heart attacks and strokes.

Rusfertide is made by a company called Protagonist Therapeutics. A big drug company called Takeda will help sell it. The FDA is expected to decide very soon whether it is safe to use.

How Does It Work?

Your body has a natural "traffic cop" hormone called hepcidin. Its job is to hold on to iron. Red blood cells need iron to be built. No iron means no new red blood cells.

Rusfertide acts like a copy of hepcidin. It locks the iron away. Without enough iron, the body cannot make too many extra red blood cells. Think of it like turning down a kitchen faucet. Less water means no overflow.

Who Is It For?

Where Does It Stand?

StepStatus
Lab and animal testing✅ Done
Phase 1 — first safety test in people✅ Done
Phase 2 — does it work in a small group?✅ Done (positive results)
Phase 3 — the big test, called VERIFY✅ Done (positive results, March 2025)
Breakthrough Therapy Designation✅ Granted (August 2025)
FDA application submitted✅ January 2026
Priority Review✅ Granted (March 2026)
Final FDA approval⏳ Pending — decision expected soon

Why Does This Matter?

Today, the main treatment for PV is phlebotomy — draining blood out of the body over and over. It is a treatment from hundreds of years ago. It hurts, it is tiring, and it means constant clinic visits.

Rusfertide could replace those blood draws with one small self-injection per week. It keeps blood thin and lowers the chance of dangerous clots. For older adults, that means fewer trips to the doctor and a lower risk of heart attack and stroke.

What We Do Not Know Yet

Common Questions

What is Rusfertide and how does it work?

Rusfertide is a new medicine for polycythemia vera, a blood cancer that makes too many red blood cells. It copies a natural hormone called hepcidin that locks iron away, so the body cannot build too many extra red blood cells.

What does the evidence actually show?

A large Phase 3 trial called VERIFY showed most patients on Rusfertide could skip blood draws for 32 weeks and felt less tired. It also kept their red blood cell count in a safer range.

How is it given?

It is a small shot under the skin, given once a week. People can learn to give it to themselves at home, instead of going to a clinic.

What are the risks and side effects?

The most common side effect is soreness or redness where the shot goes in. In the past, the FDA paused testing to check a possible cancer risk, then let testing continue. Long-term safety is still being watched.

Who should not take it?

It is only for adults with polycythemia vera. It is not for people with other conditions, and it is not yet FDA-approved. Always talk to your doctor first.

The Bottom Line

Rusfertide is a first-of-its-kind weekly injection that could replace old-fashioned blood draws for a rare blood cancer. If the FDA says yes — and a decision is expected very soon — it would give older adults an easier and safer way to manage their condition.

Sources